Remidio

Remidio develops innovative digital solutions for ophthalmic screening and diagnosis, enhancing healthcare delivery through advanced imaging technology and user-focused design. Founded in 2009 in Bangalore, India, Remidio specializes in ophthalmic health solutions. Led by CEO Anand Sivaraman, the company has engaged in six funding rounds, with its most recent Series A round on July 20, 2021, raising INR 212. 08 million from investors including Yongfah Capital Pte Ltd, Montane Ventures, and Pureland Global Venture.

The company has not undergone any significant strategic pivots or changes since its inception. Remidio specializes in developing innovative digital solutions tailored for ophthalmic screening and diagnosis, focusing on user-centric design and technology integration. Their core product offerings include the Fundus On Phone (FOP-NM), a non-mydriatic imaging device enabling fundus photography with a 45° field of view, and the Portable Slit Lamp (PSL-D20), designed for handheld slit imaging with adjustable features. Other notable products are the Instaref R20, which utilizes Shack-Hartmann aberrometer technology for precise measurement, and the Medios DR, an offline AI tool that screens for diabetic retinopathy with impressive sensitivity and specificity.

These solutions are aimed at healthcare professionals such as ophthalmologists, optometrists, and primary care physicians, and are utilized in various markets including university health systems, integrated delivery networks, and non-profit organizations across regions like India and other emerging markets. Remidio operates on a business-to-business model, providing its ophthalmic solutions primarily through direct sales to healthcare providers and institutions. The transaction structure generally involves partnerships with healthcare organizations, where clients purchase specific products based on their needs for eye care screening and diagnosis. The company's flagship products, such as the Fundus On Phone and the Portable Slit Lamp, are sold at established pricing that reflects their advanced technology and design capabilities.

In the most recent year, 2023, the company reported a revenue of INR 4,185,984. 60 and an EBITDA of -INR 578,313, indicating operational challenges. Revenue is generated from direct sales, and ongoing collaborations with clients include training and support services as part of the overall service package, ensuring high customer satisfaction and retention. Following its recent funding round in July 2021, where Remidio raised INR 212.

08 million in Series A funding, the company aims to enhance its product portfolio and expand into new geographic markets. Plans include the introduction of next-generation products focused on advanced ophthalmic diagnostics, tailored for emerging markets including Southeast Asia and Africa by 2024. The funding will facilitate product development and market entry strategies, strengthening their presence in rapidly growing regions and improving healthcare access.